Last reviewed · How we verify
P. falciparum infection
At a glance
| Generic name | P. falciparum infection |
|---|---|
| Sponsor | Seattle Children's Hospital |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Pyrexia
- Upper respiratory tract infection
- Pain
- Decreased appetite
- Gastroenteritis
- Irritability
- Swelling
- Somnolence
- Pneumonia
- Malaria
- Diarrhoea
- Rhinitis
Key clinical trials
- Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2) (PHASE2)
- Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum (PHASE1)
- A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate (PHASE1)
- Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield (NA)
- Permethrin-treated Baby-wraps for the Prevention of Malaria in Children (NA)
- A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria (PHASE1, PHASE2)
- VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection (EARLY_PHASE1)
- Chlorproguanil-Dapsone in Pregnant Women (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P. falciparum infection CI brief — competitive landscape report
- P. falciparum infection updates RSS · CI watch RSS
- Seattle Children's Hospital portfolio CI